We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,700
Open access books available

108,500
International authors and editors

1.7 M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Left Ventricular Endocardial Pacing Techniques as an Alternative for Ineffective Cardiac Resynchronization Therapy and the Role of Acute Hemodynamic Evaluation

Berry M. van Gelder\textsuperscript{1}, Patrick Houthuizen\textsuperscript{1}, Mike G. Scheffer\textsuperscript{2}, Lukas Dekker\textsuperscript{1} and Frank A. Bracke\textsuperscript{1}

\textsuperscript{1}Catharina hospital, Eindhoven
\textsuperscript{2}Maasstad hospital, Rotterdam
The Netherlands

1. Introduction

Cardiac resynchronization therapy (CRT) has become an important treatment for patients with heart failure and left ventricular dyssynchrony (Cazeau et al., 2001; Abraham et al., 2002; Auricchio et al., 2002; Cleland et al., 2005). For left ventricular (LV) pacing in CRT, transvenous placement of a lead into one of the posterolateral tributaries of the coronary sinus (CS) is the first choice. However, even with growing experience and improvement of available materials and tools placement of a lead into the coronary venous system may fail. Failures can be due to inability to engage the coronary sinus, absence of suitable side branches in the posterolateral area, coronary vein stenosis, lead instability, high stimulation threshold, phrenic nerve stimulation or a combination (Auricchio et al., 2004; Bentkover et al., 2003; Gras et al., 2002).

As alternative for surgical epicardial lead implantation, in case of failed coronary sinus implant, atrial transseptal approaches with endocardial LV lead placement have been described, using a modified transseptal puncture technique from either the right jugular vein (Jais et al., 1998; Jais et al., 2000; Leclercq et al., 1999; Jais et al., 2006) or from the left axillary vein (Sen et al., 2004). We modified the atrial transseptal technique for endocardial LV lead placement by using a standard transseptal puncture from the femoral vein, dilatation of the atrial septum and subsequent passage of the lead through the septum via the subclavian vein (Van Gelder et al., 2007). Shortly after, a second alternative technique was described for LV endocardial implantation, using a limited lateral thoracotomy with transapical insertion of the lead (Kassai et al., 2009). We also used this transapical technique in a number of patients in whom the trans-atrial septum implant was unsuccessful or contraindicated due to the presence of an artificial valve in mitral position.

Besides being an alternative for failed coronary sinus implants, the flexibility of lead positioning by both endocardial techniques also offers the possibility of an endocardial implant at a different LV site in patients not responding to CRT. The efficacy of the
endocardial lead position at different locations can be evaluated in an acute hemodynamic study using a sensor tipped pressure wire for invasive measurement of \( \frac{LVdP}{dt_{\text{max}}} \), prior to permanent implantation (Van Gelder et al., 2004).

In this chapter we describe the technique and results of the transseptal and transapical implant. The technical aspects and results of the temporary LV endocardial pacing and hemodynamic studies in patients that were nonresponders are described in detail.

2. The atrial transseptal technique

2.1 Patients and methods

In the period from January 2006 to May 2010 we attempted implantation of an endocardial LV lead in 20 patients, (10 males; mean age 68±8.6 years). All patients had standard indications for implantation of a CRT-P or CRT-D device. Clinical details are summarized in table 1.

<table>
<thead>
<tr>
<th>Sex</th>
<th>Age (years)</th>
<th>CM</th>
<th>NYHA</th>
<th>EF (%)</th>
<th>PQ (ms)</th>
<th>QRS (ms)</th>
<th>ACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pt. 1</td>
<td>M</td>
<td>54</td>
<td>ICM</td>
<td>III-IV</td>
<td>18</td>
<td>176</td>
<td>169</td>
</tr>
<tr>
<td>Pt. 2</td>
<td>F</td>
<td>71</td>
<td>DCM</td>
<td>III-IV</td>
<td>20</td>
<td>182</td>
<td>200</td>
</tr>
<tr>
<td>Pt. 3</td>
<td>M</td>
<td>58</td>
<td>DCM</td>
<td>III</td>
<td>23</td>
<td>188</td>
<td>142</td>
</tr>
<tr>
<td>Pt. 4</td>
<td>M</td>
<td>65</td>
<td>ICM</td>
<td>IV</td>
<td>28</td>
<td>212</td>
<td>168</td>
</tr>
<tr>
<td>Pt. 5</td>
<td>F</td>
<td>78</td>
<td>DCM</td>
<td>III</td>
<td>35</td>
<td>168</td>
<td>156</td>
</tr>
<tr>
<td>Pt. 6</td>
<td>F</td>
<td>68</td>
<td>DCM</td>
<td>III</td>
<td>45</td>
<td>230</td>
<td>118</td>
</tr>
<tr>
<td>Pt. 7</td>
<td>M</td>
<td>82</td>
<td>ICM</td>
<td>III</td>
<td>21</td>
<td>152</td>
<td>174</td>
</tr>
<tr>
<td>Pt. 8</td>
<td>F</td>
<td>80</td>
<td>ICM</td>
<td>III</td>
<td>25</td>
<td>AF</td>
<td>200</td>
</tr>
<tr>
<td>Pt. 9</td>
<td>F</td>
<td>62</td>
<td>DCM</td>
<td>III</td>
<td>30</td>
<td>190</td>
<td>170</td>
</tr>
<tr>
<td>Pt. 10</td>
<td>F</td>
<td>76</td>
<td>ICM</td>
<td>III-IV</td>
<td>15</td>
<td>143</td>
<td>156</td>
</tr>
<tr>
<td>Pt. 11</td>
<td>M</td>
<td>74</td>
<td>ICM</td>
<td>III-IV</td>
<td>18</td>
<td>VP</td>
<td>198</td>
</tr>
<tr>
<td>Pt. 12</td>
<td>M</td>
<td>70</td>
<td>DCM</td>
<td>III-IV</td>
<td>22</td>
<td>240</td>
<td>280</td>
</tr>
<tr>
<td>Pt. 13</td>
<td>V</td>
<td>72</td>
<td>DCM</td>
<td>III-IV</td>
<td>20</td>
<td>195</td>
<td>175</td>
</tr>
<tr>
<td>Pt. 14</td>
<td>M</td>
<td>74</td>
<td>ICM</td>
<td>III</td>
<td>23</td>
<td>238</td>
<td>198</td>
</tr>
<tr>
<td>Pt. 15</td>
<td>M</td>
<td>55</td>
<td>DCM</td>
<td>IV</td>
<td>13</td>
<td>AF</td>
<td>173</td>
</tr>
<tr>
<td>Pt. 16</td>
<td>V</td>
<td>55</td>
<td>DCM</td>
<td>III</td>
<td>25</td>
<td>138</td>
<td>140</td>
</tr>
<tr>
<td>Pt. 17</td>
<td>V</td>
<td>62</td>
<td>DCM</td>
<td>III</td>
<td>21</td>
<td>159</td>
<td>194</td>
</tr>
<tr>
<td>Pt. 18</td>
<td>M</td>
<td>66</td>
<td>ICM</td>
<td>III</td>
<td>21</td>
<td>VP</td>
<td>220</td>
</tr>
<tr>
<td>Pt. 19</td>
<td>M</td>
<td>76</td>
<td>ICM</td>
<td>III</td>
<td>27</td>
<td>VP</td>
<td>265</td>
</tr>
<tr>
<td>Pt. 20</td>
<td>V</td>
<td>64</td>
<td>ICM</td>
<td>III</td>
<td>33</td>
<td>129</td>
<td>122</td>
</tr>
</tbody>
</table>

ACT = anti coagulant therapy; AF = Atrial fibrillation; CM = Cardiomyopathy DCM = Dilated cardiomyopathy; EF = Ejection fraction; ICM = Ischemic cardiomyopathy; VP = Ventricular pacing

Table 1. Patient characteristics.
Of notice, 18 patients were on anticoagulant therapy before the implantation. None of the patients had echocardiographic evidence of left atrial or left ventricular thrombi. After the initial implantation attempt of the CS lead, 11 out of the 20 patients had developed one or more of the following complications. A high stimulation threshold (4 patients), phrenic nerve stimulation (4 patients), and/or one or more lead dislodgements (3 patients) during short term follow-up with no alternative CS locations. The remaining 8 patients had an unsuccessful implantation of a coronary sinus lead. In 6 of these patients, the right atrial and ventricular lead together with the CRT devices were implanted during the first procedure with the port of the LV lead sealed with an IS-1 plug. A transseptal procedure was performed on a later date.

In 2 patients the transseptal procedure was performed during primo implantation, when coronary sinus lead implantation was unsuccessful. In all patients we were convinced that either persuading in the primo procedure or a new attempt in the failures at follow-up, would not lead to a successful procedure. Under these conditions, the options of an alternative implant route, either epicardial with a lateral thoracotomy, or a transseptal endocardial approach were discussed with patient and/or relatives.

### 2.2 Implantation technique

The pacemaker or ICD pocket was made or reopened under local anesthesia. In primo implants right ventricular and right atrial lead were implanted first. Subsequently the subclavian vein was punctured and a 10 F sheath (Safe Sheath) was inserted, allowing obtaining access to the right atrium with an Attain Deflectable 6226 or 6227 DEF Catheter Delivery System (Medtronic Inc. Minneapolis, MN, USA). In 18 out of 20 patients implants were performed from the left pectoral area, in 2 patients from the right.

In 19 patients a standard transseptal puncture employing a Adult Transseptal (Medtronic Inc. Minneapolis, MN, USA) or a Preface 8F 307803M (Biosense Webster, Inc. Diamond Bar CA 91765, USA) sheath was performed from the right femoral vein. After transseptal puncture patients were anticoagulated with an intravenous injection of 5000 international units of heparin. A 0.035" guide wire with a length of 260 cm was inserted into the left atrium and advanced into one of the pulmonary veins or the left ventricle.

At that time the dilator of the transseptal sheath was removed from the system and a 4 cm long 6mm angioplasty balloon (Cordis Corporation – Endovascular, Warren, New Jersey, USA) inserted into the left atrium. The transseptal sheath was withdrawn into the right atrium and the balloon positioned across the septal puncture site. The balloon was inflated with contrast medium and the inflation was stored on X-ray in order to identify the indentation of the balloon as a marker of the atrial septum puncture location (Fig. 1-A). This picture was used as a road map during the procedure. The balloon was deflated and withdrawn into the transseptal sheath while the guide wire was kept in the left atrium.

The deflectable catheter inserted from the pectoral area was advanced in the right atrium and the tip curved in a rigid J-shape pointing in a left-cranial direction. Using fluoroscopy from a right and left anterior oblique view the tip of the deflectable catheter was positioned towards the atrial septum puncture side guided by the transseptal guide wire and the reference image of the balloon inflation. As a result, the deflectable catheter pointed towards the atrial septum from an inferior direction. In the first 2 patients different catheters and guide wire combinations were used to enter the left atrium through the deflectable catheter. A standard 6F right Judkins or internal mammary artery angiography catheter together with
a 0.035” hydrophilic stiff guide wire (Terumo Europe NV, Leuven, Belgium) inserted in the deflectable catheter turned out to be the best combination to enter the left atrium and was used as the first choice in the succeeding procedures (Fig. 1-B).

Fig. 1. Inflation of the 6 mm balloon at the level of the right atrial septum (arrow), panel A. Atrial septum crossed with a 6F right Judkins catheter and Terumo guide wire, panel B. Atrial septum crossed with deflectable catheter, panel C. Final position Medtronic 4076 screw-in lead position in left posterolateral area, panel D.

Different directions of the tip of the guide wire could be obtained by advancing and rotating the right Judkins catheter just outside the deflectable catheter. When the hydrophilic guide wire was in the left atrium an additional inflation of the balloon in the atrial septum was performed to ensure adequate access to the left atrium and subsequently the balloon again was withdrawn into the right atrium. Now the right Judkins catheter was advanced over the hydrophilic guide wire into the left atrium. After passing the atrial septum, the tip of the right Judkins catheter was turned in an inferior position, allowing advancement of the guide wire and the right Judkins catheter into the left ventricle. Hereafter the deflectable sheath was advanced through the atrial septum and positioned in the left ventricle at the posterolateral area (Fig. 1-C).

Occasionally, after entrance of the guide wire into the left atrium, additional dilatation of the septum with the balloon advanced from superior through the deflectable sheath was necessary to create the right direction of the slit in the septum to allow passage of the sheath. After removal of the right Judkins catheter, a standard bipolar screw-in lead Medtronic 4076-65 cm (Medtronic Inc. Minneapolis, MN, USA) was subsequently implanted through the deflectable sheath in the posterolateral area (Fig. 1-D).
After testing for pacing and sensing thresholds and excluding phrenic nerve stimulation at maximal output of the pacing system analyzer (10.0 V), the deflectable catheter was removed using a longitudinal slitter tool, which is a standard device in removing coronary sinus sheaths. The lead was sutured to the pectoral muscle and connected to the CRT device. Anticoagulant therapy was (re)instituted immediately after the procedure: dalteparine in therapeutic dose until adequate anticoagulation with an oral vitamin K antagonist (INR between 3.0 and 4.0) was obtained.
In the last patient the right Judkins was exchanged for an Attain Select catheter (Medtronic Inc, Minneapolis MN, USA), allowing insertion of a 4F Select Secure pacing lead.

2.3 Results
Successful implant of a LV endocardial lead was obtained in 19 out of the 20 patients. In the patient that failed (pt. 2) the atrial septum could not be traversed with the deflectable catheter in combination with the right Judkins catheter and hydrophilic guide wire, even after successful transseptal puncture and dilatation of the atrial septum with a 6 mm balloon. In the remaining 19 patients it was relatively easy to find the atrial perforation with the hydrophilic guide wire.

Fig. 2. Transesophageal echocardiogram showing the position of the LV pacing lead crossing the atrial septum and mitral valve (arrows). There is a low grade mitral regurgitation at the site of the pacing lead.

After entering the left atrium with the hydrophilic guide wire it was sometimes difficult to pass the right Judkins catheter and the deflectable guiding catheter into the left atrium. When this problem was encountered, an additional inflation of the 6 mm balloon prior to advancement of the deflectable catheter facilitated this maneuver. If advancement still failed, inflation of a 6 mm balloon in the atrial septum, inserted from superior over the hydrophilic guide wire through the deflectable catheter, was sufficient to enable passage of...
deflectable catheter. As indentation of the balloon was still visible at these additional inflations, it became apparent that there was significant elastic recoil around the dilatation site. After these maneuvers, the deflectable catheter could easily be passed into the LV towards the posterolateral wall in all 19 patients, followed by positioning and fixation of the lead. The mean stimulation threshold after fixation of the lead was 0.78±0.24 V, 1.2±0.5 mA at 0.5 ms pulse width, and the amplitude of the intracardiac electrogram was 14.2±9.7 mV with a slew rate of 3.1±1.0 V/s. Stimulation with 10.0 V did not result in phrenic nerve stimulation in any of the patients.

In 2 out of the first 4 patients dislodgement of the lead was observed within 24 hours after implantation. In one patient the lead could be repositioned by insertion of a stylet, in the second re-insertion of the deflectable catheter was necessary. Insufficient slack in the lead was considered as the main cause of the dislodgements. After paying attention to this phenomenon no further dislodgements were observed. Chronic stimulation threshold 2 months after implantation was 1.48±0.35V at 0.063±0.027 ms pulse width. Echocardiographic studies after implant did not show a transseptal shunt in any of the patients. In 2 patients an increase in mitral regurgitation was observed after implantation from grade I to II-III and from grade II to III. Average mitral regurgitation for the first 10 patients was grade 1.6±0.8 pre implant and 2.0±0.9 post implant (p=0.19) (Fig. 2).

There were no clinical signs of thrombo-embolic events in an average follow-up period of 32.8 ± 17.5 months. All patients improved clinically with at least 1 NYHA class. Three patients died during follow-up.

2.4 Atrial septum perforation from the pectoral area

In the previous paragraph access to the left atrium was obtained by a traditional transseptal puncture followed by dilatation of the atrial septum with a 6 mm balloon.

![Fig. 3. Intra Cardiac Echo (ICE) demonstrating tenting position (arrow) of the deflectable catheter with dilator and guide wire against the fossa ovalis (A, C). Positioning of the Medtronic 3830 lead in the posterolateral area through the Attain Select catheter (B, D).](www.intechopen.com)
A more elegant approach, avoiding working in 2 separated sterile fields, would be perforation of the septum from the device implant site. There is only one case report describing atrial septum puncture from the left pectoral area using a modified Brockenbrough needle (Sen et al., 2004). We recently performed a perforation with access to the left atrium from the left pectoral area in a 64 year old female patient, NYHA class III, with an ischemic cardiomyopathy, left bundle branch block, QRS width 132 ms, ejection fraction 28%. She had a coronary sinus lead implant in the mid cardiac vein as only accessible side branch. Unfortunately she developed untreatable phrenic nerve stimulation, which necessitated a new intervention. Due to the lack of suitable coronary sinus side branches, a transseptal approach was chosen.

After positioning a deflectable catheter (Medtronic DEF 6227), with a dilator and guide wire against the fossa ovalis using moderate pressure, tenting of the fossa ovalis was observed on intra cardiac echo (ICE), (Fig. 3). In this position 40 Watt RF energy from a electrosurgical unit ERBE ICC 200 (ERBE Elektromedizin GmbH, D-72072 Tuebingen, Germany) was applied for 2 seconds, where after the guide smoothly passed the inter atrial septum.

Advancement of the guide wire was followed by introduction of the Attain Select catheter (Medtronic Inc., Minneapolis, MN, USA) into the left atrium and subsequently into the left ventricle. After positioning the Attain Select catheter against the posterolateral wall of the left ventricle, a Medtronic SelectSecure lead was implanted in this area. After obtaining satisfactory values for pacing and sensing, the Attain Select catheter and the deflectable catheter were removed employing standard catheter slitting techniques.

Fig. 4. Tissue tracking traces of the patient with the septal perforation from the pectoral area, showing restoration of synchrony after optimization.

Patient recovered quickly and the system was optimized in the referring hospital (Dr.MGS) using echocardiographic techniques (Fig. 4). In the follow-up the patient was responder to CRT demonstrated by improvement in clinical signs of heart failure, reduction in NYHA class and reduction of LV dimensions on echocardiography.
3. The transapical implantation technique

3.1 Introduction
In our experience with transseptal LV endocardial implants, occasionally we failed to implant the LV lead. In 2 cases where introduction of the guide wire and / or catheter into the left atrium after dilatation of the atrial septum was unsuccessful; in a third patient with failure of an epicardial LV lead and a persistent left superior vena cava and one patient with a failed CS implant and an artificial valve in the mitral position, which is a contra indication for the transeptal approach, we performed a transapical implant. In these 4 patients we used a slight modification of the technique described by Kassai et al. (Kassai et al., 2009) to perform a transapical approach.

3.2 Implantation technique
The transapical implant is performed under total anesthesia with a left lateral thoracotomy at the side of the left ventricular apex. When apical pulsations are not palpable the apex can be located by transthoracic echocardiography. After opening of the thorax a small pericardial incision is made over the LV apex. Next, LV apex is visualized and a purse string suture is applied around the apex. LV is punctured though the purse string suture with an 18G needle allowing introduction of a 0.035” guide wire into the LV cavity. Over this guide wire an 8.4 F Medtronic C304-59 SelectSite deflectable catheter with a dilator is introduced into the left ventricle.

Fig. 5. Insertion place of the SelectSite deflectable lead after lateral thoracotomy. Catheter is inserted through a previous placed purse string suture around the apex (arrow). Inset shows the control mechanism of the deflectable catheter in detail. Distal curve of the deflectable catheter can be controlled by rotation of the black handle.
The external handle at the proximal end enables the operator to curve the distal end of the catheter and together with torquability of the catheter all endocardial positions can be reached. After positioning the deflectable catheter against the selected site of the LV wall, a Medtronic SelectSecure 3830-74 was screwed to the endocardium.

After obtaining satisfactory values for pacing and sensing, the deflectable catheter was removed employing standard catheter slitting techniques. Of note, the intracardiac EGM of the LV lead should display an injury pattern already before screwing, which increases after screwing and is maintained during removal of the deflectable catheter. During removal of the deflectable catheter care should be taken to preserve enough slack of the lead inside the LV cavity to prevent early dislocation.

Bleeding from the left ventricle insertion side can be controlled by the purse string suture around the puncture hole. In case of continuous bleeding an extra purse string suture with pledge material may be used to gain hemostasis.

After closure of pericardium and ribs, the lead is also fixed to muscular structures around the ribs, employing the standard fixation sleeve, leaving some extra length between both fixation points. From this place the lead is tunneled to a subcutaneous or muscular pocket located in the left pectoral region in all patients. The postoperative anticoagulant regimen was identical to the protocol for transseptal implants.

The postoperative hospitalization for these four patients was 5.8±1.0 days, which is significantly longer than after a transseptal procedure. One patient needed a re-thoracotomy at day 2 postoperative due bleeding at the site of the thoracotomy. There were no hemodynamic complications during follow up. Radiographic control revealed a stable position of the LV endocardial lead at 2 months follow-up. One example is displayed in figure 6.

Fig. 6. Left anterior oblique view of one of the patients with a transapical implantation. The left panel shows the lead position of the SelectSecure lead in the posterolateral area (arrow) 3 days after implant (left panel) and 2 months after implant in the right panel. Comparison shows the stability of the lead inside the LV cavity and at both fixation points.
3.3 Discussion and conclusion LV endocardial implantation

LV endocardial pacing can be considered as an alternative for failed coronary sinus implants, which still has a failure rate at implant of 8.4% (Leon et al., 2005). The combined failure rate at implant and short term follow-up is estimated between 10 and 15%. Although the current standard alternative for failed transvenous coronary sinus implants is a surgical epicardial approach, LV endocardial lead placement is an alternative in selected patients, either by transseptal or transapical technique.

The transseptal technique, first described by Jais et al., was later modified by Leclercq et al. using a transseptal puncture from the right jugular vein (Jais et al. 1998; Leclercq et al., 1999). Engagement of the fossa ovalis and the absence of classical anatomical landmarks make a superior approach challenging. Further, in case of implant through the jugular vein subcutaneous tunneling of the lead over the clavicle and sternum in left pectoral implants is necessary, which increases the risk of skin erosion and lead damage.

Our technique resembles the initial idea of Jais et al. but is easier to perform and has the advantage over the transseptal puncture from the jugular vein that entrance created by balloon dilatation can be used from all upper thoracic veins that are used for implantation from the right as well as the left side. Balloon dilatation of the atrial septum has been reported with a 8 mm balloon used during mitral balloon valvotomy, which did not result in a hemodynamic relevant left to right shunt at follow-up (McKay et al., 1987; Cequier et al., 1988; Palacios et al. 1989) and would therefore be unlikely with the smaller 6 mm balloon.

The risk of thrombo-embolic complications from left ventricular endocardial lead placement is a major concern for application of this technique. Not intended and unnoticed left ventricular endocardial lead placement is a potential source for thromboembolism that might result in neurological complications in patients not receiving anticoagulant therapy (Sharifi et al., 1995; Van Gelder et al., 2000). Anticoagulant therapy with a recommended target INR between 2.5 and 3.5 is mandatory in these patients, although the risk of thrombo-embolic complications seems to diminish 3 years after implantation, suggesting complete endotheliazation after this period (Sharifi et al., 1995). Long term follow-up showed no thrombo-embolic complications as long as anticoagulant therapy was maintained (Pasquie et al., 2007). In our series ninety percent (18 out of 20 patients) had already an indication for anticoagulant therapy before the decision for CRT, as is common in this patient population. During the follow-up of 32.8±17.5 months in this study no thrombo-embolic complications with permanent damage have been noticed so far.

Mitral valve dysfunction due to the presence of the endocardial lead passing the mitral valve was only observed in 2 of the first 10 patients, in whom conventional 7F screw-in leads were used. Application of a very soft and flexible 4F lead (Medtronic SelectSecure 3830) gave a further reduction of mechanical effects on mitral valve function.

The generally accepted alternative for failed coronary sinus pacing is surgical epicardial placement of the LV lead through a limited lateral thoracotomy or a thoracoscopic approach. However, thoracotomy can be contraindicated due to previous cardiac surgery or poor general condition. Further, complications of surgery can be anticipated as well. Joshi et al. reported post operative complications after a robotically assisted left ventricular lead placement in 7 out of 42 patients (Joshi et al., 2005). Koos et al. reported the comparison of coronary venous lead placement versus a limited lateral thoracotomy, which was in favor of the transvenous lead placement with respect to post implant hospitalization, increase in functional capacity and mortality at 1 year follow-up (Koos et al., 2004).
Apart from 2 dislodgement of the left ventricular lead in our early experience with transseptal lead placement, there were no procedure related complications in this cohort. Our preliminary results therefore suggest the feasibility and safety of LV transseptal endocardial lead implantation. A main advantage is the possibility in case of a failed coronary sinus lead positioning to implant the left ventricular lead during the same procedure from the already created sub pectoral entry site, either from the right or left pectoral area.

Considerations regarding anticoagulant regimen and freedom of selecting any pacing site inside the LV of the transseptal approach can also be applied to the transapical approach. There are 2 main differences between both techniques. First, the transapical approach has the advantage that the LV lead is not crossing the mitral valve with the potential to cause dysfunction, which was, however, almost completely eliminated by using very flexible 4F leads.

The risk of mitral valve endocarditis as mentioned by Kassaï et al., due to close and permanent contact between lead and the mitral valve, is not supported by the long-term follow-up of LV endocardial leads as reported by Pasqué et al. (Kassaï et al., 2008; Kassaï et al., 2009; Pasqué et al., 2007). It will be clear that in the presence of an artificial mitral valve the transseptal approach is contra indicated. In our limited experience the transapical approach has a 100% success rate and a predictable operation time of approximately 1.5 hour. A second difference is that the impact on hospitalization and morbidity is higher for the transapical approach due to the lateral thoracotomy. The average postoperative hospitalization was 5.8±1.0 days versus 1 day for transseptal approaches.

It can be concluded that both technique are safe and feasible as an alternative for failed CS implants. The preference of the operator determines the choice of the technique; whereas both methods have there specific advantages and disadvantages which may play a role in the final choice.

4. Acute hemodynamic testing and ineffective CRT

4.1 Introduction

Left ventricular endocardial pacing is initially considered for patients with failed coronary sinus implants or preliminary lead failure during follow-up. However, nonresponders in CRT can be related to patient selection, LV lead placement, presence of scar tissue, or inadequate optimization of the atrio-ventricular (AV) and/ or interventricular (V-V) interval (Yu et al., 2005).

The application of LV endocardial pacing either by transseptal or transapical approach offered the operator the freedom of selection the optimal pacing site. A second argument for LV endocardial pacing is the superior hemodynamic effect as compared to epicardial pacing. (Garrigue et al., 2001; van Deursen et al., 2008).

After our initial experience with transseptal LV endocardial lead implantations for failed implants or early lead failure, the following questions were raised:

1. Is there a role for LV endocardial pacing in nonresponders?
2. Can the hemodynamic effect of resynchronization be improved by endocardial pacing and/ or an optimal lead position?
3. Can the hemodynamic effect be predicted prior to implantation from a temporary hemodynamic pacing study?
4. Can all pacing modalities be performed in a temporary set up?
The use of LVdP/ dtmax for selecting the optimal pacing site and evaluation of the optimal setting of AV and V-V interval has been shown in the past (Butter C et al. 2001; Soliman et al. 2009; van Gelder et al., 2007b). The results of the measurements, which are not depending on the operator’s interpretation, are immediately available during the study. This implies that the method is extremely suitable during decision making at implantation to determine the hemodynamic effect of a left ventricular pacing site. The rapid hemodynamic stabilization after changing pacing parameters also enables the operator to perform a high number of measurements in a relative short period of time, which makes the method less sensitive to changing baseline conditions as demonstrated in the majority of our studies (Fig. 7).

Fig. 7. Recording of LV pressure (upper tracing) and LVdP/ dt (lower tracing) showing the transition for intrinsic to biventricular pacing. The example shows the rapid hemodynamic stabilization after extreme hemodynamic changes.

The procedure is minimal invasive and requires only 2 hours immobilization for the patient, which makes it also suitable for use in an out-patient setting. Supported by this knowledge we started hemodynamic evaluation of nonresponders with a temporary pacing study at multiple endocardial LV locations.

4.2 Patients and methods
Twelve patients, all males, age 75.4±7.4 years, 1 dilated and 11 ischemic cardiomyopathy, NYHA class III-IV; ejection fraction 20.1±6.2% underwent a temporary hemodynamic pacing study. Eight patients were nonresponders, 3 were failed CS implants and 1 was evaluated as a candidate for CRT. The latter patient had a dual chamber ICD and progressive heart failure associated with right bundle branch block (RBBB). There were 2 more patients with a RBBB, 5 with a LBBB and 4 with RV pacing as baseline rhythm.
In all patients the hemodynamic effect of LV endocardial pacing was evaluated from the posterolateral (PL) basal, the PL mid, the apical and mid septal LV segment, employing LVdP/ dmax measured with a 0.014” RADI pressure wire and a temporary pacing wire positioned retrograde or transseptal into the LV. The set-up for the temporary study is schematically shown in the following figure. (Fig. 8)

Fig. 8. Schematic presentation of the temporary hemodynamic pacing study.

The exploring electrode is used for temporary LV pacing either AV sequentially, or combined with the implanted system in a biventricular mode with the option of using a V-V interval.

Fig. 9. Set up of the 6F guide catheter with RADI pressure wire and temporary bipolar screw-in lead both inserted through the guide catheter.

For hemodynamic evaluation of a selected pacing site the AV (for LV pacing) and AV and V-V (for BiV pacing) were optimized. A temporary atrial electrode has to be inserted to
synchronize the external and implanted system. In the transseptal set-up a 6F guide catheter, multipurpose or internal mammary catheter, are inserted through the 8F transseptal sheath. For femoral or radial approach the same guide catheter can be used employing a 6F sheath at the arterial entrance site, as shown in figure 9.

Fig. 10. Example of radiographic pictures in a left anterior oblique position of the 4 locations that were hemodynamically tested during the temporary pacing study. The percentage increase in LVdP/ dt compared to baseline is mentioned for every position.

4.3 Results
4.4 Failed coronary sinus implants (2 pts)
Two patients developed a high stimulation threshold, approaching the level of exit block. Both had a successful CS implant respectively 1 and 2 years before with placement of the lead in the only accessible coronary sinus side branch. The latter was the reason for the temporary study to justify implantation of an endocardial lead as a replacement of the failing CS lead.

In the first patient, a 76 year old male with ICM, who was pacemaker dependent LVdP/ dtmax decreased to 321 mmHg/ s when programmed to RV pacing, thus imitating complete failure of the LV lead. Biventricular pacing from PL-basal, PL-mid, LV apex, LV septum resulted in a LVdP/ dtmax of respectively 994, 933, 741, and 813 mmHg/ s, whereas the CS lead, which was in a PL basal position resulted in 967 mmHg/ s. Patient underwent a successful transseptal implant of an endocardial LV lead in the PL-basal area.

The second patient with an extreme high LV threshold, had a 17% increase in LVdP/ dt with the CS lead, which was positioned in a PL basal position. Temporary pacing from other
endocardial positions did not improve this increase. CS pacing could be maintained at maximum LV output setting. A LV endocardial lead will be implanted at generator change to avoid premature battery depletion of the new device.

4.5 Nonresponders (10 pts)

In 2 patients 74 and 79 years old, both with ICM, and an ECG with right bundle branch block (RBBB), QRS duration 170 and 175 ms did not respond to CRT with leads positioned in the CS. The hemodynamic pacing study revealed no improvement in LVdP/ dtmax with the implanted system. LV pacing from the 4 endocardial positions could not increase LVdP/ dt above the intrinsic baseline value in both patients.

In one patient with a dual chamber ICD and increasing heart failure, but with a RBBB, implantation of a CRT system was considered. Prior to implant a temporary pacing study was performed to evaluate the hemodynamic effect of CRT. LV endocardial pacing showed an increase in LVdP/ dtmax when pacing from the PL basal area of 17%. CS angiography showed a suitable side branch in the target area and a successful implant was performed in the preselected location.

Four patients, 1 with DCM and 3 with ICM, with LBBB in 3 patients and RV pacing in 1 patient, were all nonresponders. The mean ejection fraction prior to implant was 17.5±6.5%. Hemodynamic pacing study revealed an increase of LVdP/ dtmax at the optimal endocardial location of 25.2±4.8%. In 3 patients the optimal location was PL-basal, and PL-mid in 1 patient. The patients with the lowest ejection fraction of 13 and 12% underwent a successful transseptal and transapical implant respectively. One of these patients with DCM, turned out to be superresponder with a reduction of NYHA class IV to II, an increase in ejection fraction from 13 to 45% and a decrease in the end-diastolic and systolic diameter to 61 and 47 mm, respectively, with only minor mitral regurgitation (Bracke et al. 2010).

In one nonresponder (LBBB, QRS duration 206 ms), who was not optimized but programmed to a standard setting with a V-V interval of 40 ms (LV pre-activation), LVdP/ dtmax was 1017 mmHg/ s. During hemodynamic testing LVdP/ dtmax with RV pacing was 1113 mmHg/ s, whereas CS pacing resulted in a LVdP/ dtmax of 870 mmHg/ s. All endocardial positions except LV apex had a lower LVdP/ dtmax than with RV pacing. LV apex had the same LVdP/ dt as RV pacing, which was not surprising, because of the similarity in anatomical positions of both pacing modalities. Changing the V-V timing to -40 ms (RV pre-activation), and selecting the proximal CS electrode increased LVdP/ dtmax for biventricular pacing to 1193 mmHg/ s (+17.3%). Patient clinically improved after optimization with 1 NYHA class.

In one patient who showed increasing heart failure after initial response to CRT, was referred to our institution for hemodynamic evaluation. Hemodynamics at the current setting showed a LVdP/ dtmax value of 720 mmHg/ s. After optimization of the AV and V-V interval and selecting the proximal CS electrode of the dual unipolar lead instead of the distal electrode LVdP/ dtmax could be increased with 11.5%, which resulted in a significant clinical improvement with loss of weight and reduction of diuretics.

The last patient, male 87 years, NYHA class III, ejection fraction 25%, LBBB with QRS duration of 154 ms presented as a clinical nonresponder. Baseline LVdP/ dt was 827 mmHg/s and increased with 45% by optimized biventricular pacing employing the implanted CS lead. In the best endocardial position (PL-basal) a gain of 51% could be obtained. Although left ventricular remodeling with reduction of end-diastolic and systolic diameter was significant, patient did subjectively not improve. Presumably, patient’s
symptoms were most probably associated with increasing age depending physical limitations instead of failing CRT.

### 4.6 Hemodynamic effect related to pacing site

The effect of LV pacing as related to the investigated pacing sites, posterolateral-basal (PL-bas), posterolateral-mid (PL-mid), LV apical (LV-apic) and LV midseptal (LV-sept) position is illustrated in fig. 11.

![Fig. 11. Graphic display of percentage increase of LVdP/ dt at 4 endocardial LV locations.](image)

The average of the optimal location (Opt-loc) is displayed in the left bar.

The posterolateral basal position is on average the best position, demonstrated by the maximum increase in LVdP/ dt in 7 out of the 10 patients. In 1 patient the posterolateral-mid position gave the best result. In 2 patients LV pacing from the LV apex had the highest LVdP/ dt. Of note, one patient with the highest value of LVdP/ dt with LV apex pacing was one of the patients with a RBBB. The second patient was the patient in whom all LV endocardial locations resulted in a lower LVdP/ dt than RV apex pacing, but LV apex was the best of 4 locations, which is reasonable because LV apex pacing has the best similarity with RV apex pacing.

In all nonresponders where the effect of LV epicardial pacing from the CS was compared to the effect at the endocardial counterpart, we could not find a significant difference between epicardial and endocardial stimulation in this small series of patients. Epicardial stimulation from the CS position resulted in an increase in LVdP/ dt of +7.1%±2.5%, whereas from the endocardial counterpart an increase of 6.7%±4.1% was measured, an observation which is in contrast with other studies (Garrigue et al., 2001; Van Deursen et al., 2007; Van Deursen et al., 2008).

In all nonresponders the increase in LVdP/ dt by CS pacing was below 10%. In 4 nonresponders a low response could be anticipated because of lead positions in the anterolateral vein (2 pts) and mid cardiac vein (2 pts).
5. Discussion

LV endocardial pacing is an alternative for failed coronary sinus implants as illustrated in the first section of this chapter. The choice for application of endocardial LV pacing in case of failed CS implant is based on a risk analysis in which factors like age, physical condition, degree of heart failure and the presence of anticoagulant therapy play a role. Remains the question, should hemodynamic testing for the evaluation of the effect of LV pacing in patients with failed CS implants be performed prior to the LV endocardial implant?

The answers that we get from the temporary hemodynamic studies are twofold. First, it is a quantification of the improvement that can be obtained with LV endocardial pacing, expressed as the increase in LVdP/dt max. Second, the pacing site where this optimal effect is obtained is determined and is used as the target area for the permanent implant. The latter justifies hemodynamic testing in failed implants with proper patient selection, or short term failure in patients that are responding to CRT during this short follow-up, in whom a transseptal implant is considered.

In patients not responding to CRT due to a suboptimal position of the CS lead, implant of an endocardial LV lead can be considered. Hemodynamic evaluation in a temporary setting seems to be mandatory prior to the implant procedure, in order to determine the effect on contractility at the optimal endocardial site and the location of this site. This temporary study prevents implants of a LV endocardial lead in patients in whom, based on the outcome of the temporary study, with an increase in LVdP/dt max of less than 10% no clinical improvement can be anticipated. On the other hand, patients that show an increase in LVdP/dt over 15% from an endocardial location are suitable candidates for an endocardial implant and the optimal site in the temporary study determines the target area for the permanent implant.

Implantation of an additional CS lead, thus creating triple site ventricular stimulation in nonresponders is suggested by Leclercq et al., who demonstrated improvement in cardiac volumes by echocardiographic techniques in this configuration over biventricular stimulation (Leclercq et al., 2008). Although the effect and technique of triple ventricular stimulation needs further investigation (Auricchio & Prinzen, 2008), the technique is not feasible in the patient category with failed CS implants or short term failure of a single CS lead.

From our experience it became obvious that in patients with LBBB the posterolateral basal area is the optimal site with a significant lower hemodynamic response from different locations like the septal and apical segment. From this experience it is difficult to understand that in larger studies (MADIT CRT), with no specific focus on this item, is concluded that the location of LV stimulation has no effect on clinical outcome. In spite of the small number of patients and a non-homogeneous patient population according to their electrocardiographic presentation, it is clear that in nonresponders an increase in LVdP/dt of less than 10% is objectivated. If pacing from a different LV location with a rise in LVdP/dt over 15% is initialized these patients became responders to CRT.

After measurement of the hemodynamic effect on LVdP/dt in a nonresponder at the programmed pacing parameters, optimization of AV and V-V interval should be performed to exclude a suboptimal setting of AV and V-V interval as a contributor to non response. If the patient also has a CS dual unipolar lead, the effect of selecting a different stimulation electrode should also be evaluated. In 2 of our patients improvement in LVdP/dt max as well as clinical status could be obtained by optimization of AV, V-V interval and selection of
the CS pacing electrode. One can speculate that development of quadrripolar CS leads with programmable pacing configurations may contribute to a further optimization of CRT.

6. Conclusion

LV endocardial pacing from a transseptal or transapical approach can be considered after failed CS implant or nonresponsiveness to CRT. The tentative benefit of a LV endocardial implant can be hemodynamically evaluated by measurement of LVdP/dt in a temporary setup. The endocardial postero-lateral area proved to be significant better than apical and mid-septal locations in patients with LBBB. In this small series the superior effect of endocardial pacing compared to the epicardial counterpart could not be objectivated from the hemodynamic evaluation.

7. References


Aurichio A, Prinzen FW. Cardiac Resynchronization Therapy: The more pacing sites, the better the outcome? *J Am. Coll. Cardiol.* 2008;51;1463-1465.


Bracke FA, Houthuizen P, Rahel BM, and van Gelder BM. Left ventricular endocardial pacing improves the clinical efficacy in a non-responder to cardiac resynchronization therapy: role of acute haemodynamic testing. *Europace* 2010; doi:10.1093/ europace/ euq043.


The book focuses upon clinical as well as engineering aspects of modern cardiac pacemakers. Modern pacemaker functions, implant techniques, various complications related to implant and complications during follow-up are covered. The issue of interaction between magnetic resonance imaging and pacemakers are well discussed. Chapters are also included discussing the role of pacemakers in congenital and acquired conduction disease. Apart from pacing for bradycardia, the role of pacemakers in cardiac resynchronization therapy has been an important aspect of management of advanced heart failure. The book provides an excellent overview of implantation techniques as well as benefits and limitations of cardiac resynchronization therapy. Pacemaker follow-up with remote monitoring is getting more and more acceptance in clinical practice; therefore, chapters related to various aspects of remote monitoring are also incorporated in the book. The current aspect of cardiac pacemaker physiology and role of cardiac ion channels, as well as the present and future of biopacemakers are included to glimpse into the future management of conductio system diseases. We have also included chapters regarding gut pacemakers as well as pacemaker mechanisms of neural networks. Therefore, the book covers the entire spectrum of modern pacemaker therapy including implant techniques, device related complications, interactions, limitations, and benefits (including the role of pacing role in heart failure), as well as future prospects of cardiac pacing.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
